

Larry Hogan, Governor · Boyd K. Rutherford, Lt. Governor · Dennis R. Schrader, Secretary

October 14, 2021

RE: Urgent Maryland AIDS Drug Assistance Program (MADAP) regulations - Public listening session

Thank you for participating in the Maryland Department of Health's (MDH) recent public listening session regarding the repeal of the Urgent Maryland AIDS Drug Assistance Program (MADAP) enrollment option. MDH is still accepting comments from the public on the repeal of these regulations.

As noted during the listening session on October 4, 2021, the repeal of Urgent MADAP and its associated regulations will not affect the provision of MADAP. Eligible Maryland residents who require access to antiretroviral therapy will still be able to enroll with and participate in MADAP. The proposed repeal is the result of recent policy change from the Health Resources and Services Administration (HRSA), which noted Urgent MADAP is currently non-compliant with federal Ryan White funding provisions, and that all federal Ryan White funding could be discontinued if Urgent MADAP is not terminated.

Despite the federal requirement to terminate this enrollment option, MDH will continue to support Marylanders' access to health coverage and pharmaceuticals through MADAP. Accordingly, MDH will convene a monthly community of practice and a monitored online discussion group where members can receive support and input from program staff. MADAP, in association with the community of practice, will develop additional resources for effective patient navigation tools to assist providers in meeting the evolving needs of MADAP program participants and applicants.

Please contact Jody Sheely at Jody.Sheely@maryland.gov with any further questions or concerns.